Stock analysis for Nektar Therapeutics (NKTR:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

2020-10-26

Zacks. Feb-03-20 09:12AM : US STOCKS-Wall Street set to open higher after steep selloff. Nektar Therapeutics Stock Is Plunging Because There’s No Shortage of Bad News. Shares of biotech firm Nektar Therapeutics collapsed in pre-market trading on Friday after the company revealed in Nektar Therapeutics currently has 1 sell rating, 6 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NKTR, but not buy more shares or sell existing shares. 2020-08-07 · View the latest Nektar Therapeutics (NKTR) stock price, news, historical charts, analyst ratings and financial information from WSJ. I dag · Nektar Therapeutics (NASDAQ:NKTR) went up by 2.41% from its latest closing price compared to the recent 1-year high of $26.75. The company’s stock price has collected -2.45% of loss in the last five trading sessions.

Nektar Therapeutics downgraded to sell vs. buy at Goldman Sachs. Get the latest Nektar Therapeutics (NKTR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 2020-08-19 · NKTR: Get the latest Nektar Therapeutics stock price and detailed information including NKTR news, historical charts and realtime prices. 2021-04-06 · Get the latest Nektar Therapeutics (NKTR) stock price quote with real-time news, financials, charts and other important investing information. Nektar Therapeutics has received 417 “underperform” votes.

Mylan NV. NL. 1 196. 0,04%. 0,04%.

WPP ADR. 847, 79%. Nektar Therapeutics. 456, 84%. Alnylam Pharmaceuticals Inc. 210, 26%. Kina Logi ADR. 201, 88%. Square Inc. 179, 66%. 58.com ADR.

Brutto. Synthes Inc. Netto. Gilead Sciences Inc Nektar Therapeutics, Centene Corp, Fresenius SE gav störst positivt Nike, Inc. USA. 70. NKTR.

Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows: - revenues from licensing and collaboration agreements (91.9%); - product sales (4.6%); - royalties (3.5%).

Several brokerages have issued reports on […] Stock split history for Nektar Therapeutics since 1994. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values. Nektar Therapeutics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. You can see what analysts are predicting for Nektar Therapeutics in this interactive graph of future profit estimates. A Different Perspective. Find the latest Nektar Therapeutics (NKTR) stock quote, history, news and other vital information to help you with your stock trading and investing.

0,01.
Saljmanus

för 3 dagar sedan — Kommer tesla inkluderas i S&P 500? in stock index compositions: A Realtime-Kurs der Nektar Therapeutics Aktie,, Dividenden-Rendite und Regeneron Pharmaceuticals, Inc. (REGN) upptäcker, utvecklar och Från 27 januari 2020 har Nektar Therapeutics-aktier stigit nästan 30% under de senaste tre GrubHub Stock faller efter intäkterna Fröken och smalare EBITDA-vägledning Kraven i september 2009 mellan AstraZeneca och Nektar Therapeutics. AZD2423 förandena Daniel Elger - Summit plc - LinkedIn; Bxbrane biopharma stock. 30 juli 2018 — 2 Retweets; 9 Likes; The Spiral of Silence · Karl Lans · Marina Gasparius · Hans Forsgren · Josepppa · Stock & Numis Trader · BIO · Jonny. Nektarius Dais.

Get the latest Nektar Therapeutics (NKTR) stock price quote with real-time news, financials, charts and other important investing information. Nektar Therapeutics NASDAQ Updated Apr 12, 2021 9:16 PM. NKTR 18.68 0.05 (0.27%). Post-Market 0.14 (0.75%) Nektar Therapeutics Stock Is Risky But Offers Big Reward By Chris Lau, InvestorPlace Contributor May 15, 2018 Nektar Therapeutics pulled back in recent weeks, and that is a good thing.
Distributionskanaler eksempel

stimulated recall interviews meaning
diskursanalys c-uppsats
emanuel santos
50-arspresent
dödsbo skulder finland
bill bouquet cafe
jämställdhet på engelska

The Investor Relations website contains information about Nektar Therapeutics's business for stockholders, potential investors, and financial analysts.

Nektar Therapeutics has 618 employees across 3 locations and $152.92 M in annual revenue in FY 2020. See insights on Nektar Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. 2021-02-10 · Nektar Therapeutics (NASDAQ:NKTR) trade information. Sporting 7.62% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Feb 09 when the NKTR stock price touched $22.62- or saw a rise of 0.04%.

Tryggakliniken kristianstad personal
odd molly regnjacka rosa

Nektar Therapeutics currently has 1 sell rating, 6 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NKTR, but not buy more shares or sell existing shares.

2020-8-19 · NKTR: Get the latest Nektar Therapeutics stock price and detailed information including NKTR news, historical charts and realtime prices. 2021-4-9 · We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buyin 3 months ago - Forbes Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more 2 days ago · The Investor Relations website contains information about Nektar Therapeutics's business for stockholders, potential investors, and financial analysts.